ClinVar Miner

Submissions for variant NM_000153.4(GALC):c.1814dup (p.Tyr605Ter)

gnomAD frequency: 0.00002  dbSNP: rs766007316
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000781391 SCV000919386 likely pathogenic Galactosylceramide beta-galactosidase deficiency 2017-10-31 criteria provided, single submitter clinical testing Variant summary: The GALC c.1814dupA (p.Tyr605X) variant results in a premature termination codon, predicted to cause a truncated or absent GALC protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant was found in 2/244526 control chromosomes (gnomAD) at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALC variant (0.0022361). The variant of interest has not, to our knowledge, been reported in affected individuals via publications. An internal patient with Krabbe disease diagnosed as an infant (<1 yo) carried this variant homozygously. A clinical diagnostic laboratory cites the variant with a classification of "pathogenic." Taken together, this variant is classified as likely pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV000781391 SCV001382219 pathogenic Galactosylceramide beta-galactosidase deficiency 2023-08-09 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 633226). This variant is also known as c.1766dupA. This premature translational stop signal has been observed in individual(s) with Krabbe disease (PMID: 30777126). This variant is present in population databases (rs766007316, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Tyr605*) in the GALC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GALC are known to be pathogenic (PMID: 7437911, 9272171, 16607461).
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV001724154 SCV001959367 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV001724154 SCV001975005 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.